RxDoctor Payments Data

Gregory Bernstein, MD

Urology · Alexandria, VANPI 1275553836

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,505 of the $17,572 with a category attached, or 71.2%. Procept Biorobotics Corporation accounts for 77.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $12,068 and has fallen 97.3% since, to $328 in 2025.

$17,572in general payments, 2019–2025

Across 122 payments — averaging $144.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$14K
  • Boston Scientific$2K
  • EDAP Technomed Inc$714
  • Endo Pharmaceuticals Inc.$651
  • Coloplast$194
  • Laborie Medical Technologies Corp.$75
  • plus $662 from 19 others

What the payments were for

  • Consulting fees$12,50571%
  • Travel & lodging$1,0096%
  • Food & beverage$4,03223%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,572 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$165,195
Medicare patients
444
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$13,775
Tamsulosin Hcl167$2,419
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$2,371
Finasteride124$1,276
Dutasteride37$1,224
Alfuzosin Hcl ErAlfuzosin Hcl60$1,149
Silodosin12$949
Oxybutynin Chloride ErOxybutynin Chloride20$637
Levofloxacin26$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$63$13,77512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.

Other urology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →